Gemifloxacin MesylateThird Party Manufacturing in India

Gemifloxacin works by inhibiting DNA synthesis through dual targeting of bacterial topoisomerase enzymes. It binds to both DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication, transcription, and repair. DNA gyrase introduces negative supercoils into bacterial DNA to facilitate replication, while topoisomerase IV separates interlinked daughter chromosomes during cell division. By stabilizing the enzyme-DNA cleavage complex, gemifloxacin prevents re-ligation of the DNA strands, causing irreversible damage to the bacterial genome and cell death.

As a fourth-generation fluoroquinolone, gemifloxacin demonstrates a broad spectrum of activity against both gram-positive and gram-negative bacteria. Its enhanced affinity for topoisomerase IV makes it particularly effective against Streptococcus pneumoniae, including penicillin-resistant and macrolide-resistant strains. Gemifloxacin also shows good activity against respiratory pathogens such as Haemophilus influenzae, Moraxella catarrhalis, and atypical organisms including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila. The 1,8-naphthyridine core structure contributes to its improved pharmacokinetic profile compared to earlier fluoroquinolones.

Therapeutic Uses

Gemifloxacin is prescribed for the treatment of respiratory tract infections:

• Community-Acquired Pneumonia (CAP): Effective for mild to moderate CAP caused by susceptible organisms, including drug-resistant S. pneumoniae
• Acute Bacterial Exacerbation of Chronic Bronchitis (AECB): Indicated for exacerbations caused by H. influenzae, M. catarrhalis, and S. pneumoniae
• Respiratory Infections with Atypical Pathogens: Active against Mycoplasma, Chlamydia, and Legionella species

Why Manufacturers Choose Gemifloxacin

Gemifloxacin mesylate third party manufacturing in India serves both the domestic market and export destinations. Indian manufacturers with WHO-GMP certification produce gemifloxacin 200mg tablets for PCD franchise partners and institutional buyers. The molecule occupies a niche position in the respiratory antibiotic market, competing with other advanced fluoroquinolones like levofloxacin and moxifloxacin.

For contract manufacturers, gemifloxacin mesylate offers opportunities in tablet production with well-established formulation processes. The API is well-characterized and supply chains are mature across the Indian pharmaceutical sector. Consistent demand from pulmonology and infectious disease treatment makes this a stable molecule for manufacturing portfolios targeting the respiratory segment.